Promising bile duct cancer combo trial halted early
NCT ID NCT05921760
First seen Feb 15, 2026 · Last updated May 24, 2026 · Updated 15 times
Summary
This early-stage trial tested a combination of ivosidenib (a targeted pill) plus two immunotherapy drugs (nivolumab and ipilimumab) in 7 adults with advanced IDH1-mutated bile duct cancer that had already been treated. The study was stopped by the sponsor before the expansion phase, so only safety results from the first phase are available. The goal was to see if the combination was safe and tolerable, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDH1-MUTANT CHOLANGIOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, Maryland, 21231, United States
-
UCLH
London, NW1 2PG, United Kingdom
-
UCSF - Medical Center at Mission Bay
San Francisco, California, 94158, United States
-
Ucsf Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.